SAN DIEGO--(BUSINESS WIRE)--Dec. 13, 2017--
Quidel Corporation (NASDAQ: QDEL), a provider of rapid diagnostic
testing solutions, cellular-based virology assays and molecular
diagnostic systems, announced that it plans to file its required report
on Form 8-K/A with the Securities and Exchange Commission (the
“Commission”) after market close on Tuesday, December 19, 2017. The Form
8-K/A will amend Quidel’s prior report on Form 8-K filed with the
Commission on October 6, 2017 that related to Quidel’s completed
acquisition of the Triage and BNP Businesses. The amendment is expected
to include the required audited abbreviated statements of assets
acquired and liabilities assumed and of revenues and direct expenses of
the Triage and BNP Businesses together with the required pro forma
information.
Following the reporting of the required financial statements and pro
forma information, Douglas Bryant, president and chief executive
officer, and Randy Steward, chief financial officer, will host an
investment community conference call on Wednesday, December 20, 2017
beginning at 8:30 a.m. Eastern Time (5:30 a.m. Pacific Time) to discuss
the results and answer questions. During the conference call, the
company will also discuss business and financial developments and
trends. The company's statements may contain or constitute material
information that has not been previously disclosed.
To participate in the live call by telephone from the U.S., dial
877-930-5791, or from outside the U.S., dial 253-336-7286, and enter the
audience pass code 667-9477.
A live webcast of the call can be accessed on the Investor Relations
section of the Quidel website (http://ir.quidel.com).
The website replay will be available for 14 days. The telephone replay
will be available for 48 hours beginning at 11:30 a.m. Eastern Time
(8:30 a.m. Pacific Time) on December 20, 2017 by dialing 855-859-2056
from the U.S., or by dialing 404-537-3406 for international callers, and
entering pass code 667-9477.
About Quidel Corporation
Quidel Corporation serves to enhance the health and well-being of people
around the globe through the development of diagnostic solutions that
can lead to improved patient outcomes and provide economic benefits to
the healthcare system. Marketed under the Sofia®, QuickVue®, D3® Direct
Detection, Thyretain®, Triage® and InflammaDry® leading brand names, as
well as under the new Solana®, AmpliVue® and Lyra® molecular diagnostic
brands, Quidel’s products aid in the detection and diagnosis of many
critical diseases and conditions, including, among others, influenza,
respiratory syncytial virus, Strep A, herpes, pregnancy, thyroid disease
and fecal occult blood. Quidel's recently acquired Triage® system of
tests comprises a comprehensive test menu that provides rapid,
cost-effective treatment decisions at the point-of-care (POC), offering
a diverse immunoassay menu in a variety of tests to provide you with
diagnostic answers for quantitative BNP, CK-MB, d-dimer, myoglobin,
troponin I and qualitative TOX Drug Screen. Quidel’s research and
development engine is also developing a continuum of diagnostic
solutions from advanced immunoassay to molecular diagnostic tests to
further improve the quality of healthcare in physicians’ offices and
hospital and reference laboratories. For more information about Quidel’s
comprehensive product portfolio, visit quidel.com.
View source version on businesswire.com: http://www.businesswire.com/news/home/20171213006119/en/
Source: Quidel Corporation
Quidel Contact:
Quidel Corporation
Randy Steward
Chief
Financial Officer
(858) 552-7931
or
Media and Investors
Contact:
Quidel Corporation
Ruben Argueta
(858) 646-8023
rargueta@quidel.com